Background. The clinical utility of carbapenems is under threat because of the emergence of acquired metallob-lactamase (MBL) genes. We describe the first outbreak in Australia of infection and/or colonization with gramnegative pathogens carrying the MBL gene bla .
Ambler class B metallo-b-lactamases (MBLs), now reported in Asia [1] , Europe [2, 3] , North America [4] , and South America [5] . These enzymes (IMP-, VIM-, SPM-and GIM-types) have a broad substrate profile and often confer high-level resistance to all b-lactams except aztreonam. Unlike class A b-lactamases, MBLs are not inhibited by clavulanic acid, tazobactam, or sulbactam; but, because of their zinc dependence, they are susceptible to the ion chelator EDTA. Acquired MBLs have now been detected in a range of organisms, including Pseudomonas aeruginosa [2] , Acinetobacter species [6] , and Enterobacteriaceae [7] , but rarely has a hospital outbreak been described in which multiple gram-negative genera are involved [8] .
The first IMP-type MBL enzyme was described in Japan in 1991 [9] . Since then, 18 IMP-variant enzymes have been reported [10] . The bla gene, coding the IMP-4 enzyme, has recently been described in Acinetobacter species isolates from Hong Kong [1] and a Citrobacter youngae isolate from the People's Republic of China [11] . Of particular concern, the bla IMP-4 gene was identified on a class 1 integron residing on a large conjugative plasmid [11, 12] . Such genetic elements are critical for the acquisition, maintenance, and dissemination of resistance in gram-negative organisms [13] .
We recently reported a carbapenem-resistant P. aeruginosa isolate carrying the bla gene that was recovered from blood culture [14] . Subsequently, an outbreak of infection and/or colonization with MBL-producing gram-negative organisms occurred at our institution. The objective of this study was to describe the microbiological, clinical, and epidemiological features of this outbreak.
MATERIALS AND METHODS
The study was conducted between January and July, 2004, at The Alfred Hospital, a 320-bed tertiary care institution in Melbourne, Australia. The hospital has a 36-bed intensive care unit (ICU) which is divided into medical and surgical ICUs and specializes in trauma, burns, and heart-lung transplantation. Gram-negative organisms cultured from clinical isolates underwent identification and initial susceptibility testing using an automated system (Vitek; bioMérieux). Isolates with resistance to carbapenems and/or resistance to other broad-spectrum blactams, such as ceftazidime or ticarcillin-clavulanate, underwent phenotypic MBL screening. Organisms known to inherently carry an MBL gene, such as Aeromonas hydrophilia, Flavobacterium species, and Stenotrophomonas maltophilia, were excluded.
A phenotypic MBL screening plate was designed, which included 3 components: (1) a double-disc synergy test that used an imipenem disc containing 10 mg of imipenem placed 20 mm (center to center) from a filter disc containing 10 mL of EDTA at a concentration of 100 mmol/L; (2) 2 imipenem discs placed 25 mm apart (center to center), 1 containing 10 mL of EDTA at a concentration of 100 mmol/L, to detect an inhibition zone size difference of 14 mm; and (3) an aztreonam disc containing 30 mg of aztreonam to detect aztreonam susceptibility. IsoSensitest agar (Oxoid) with a 1-in-10 dilution of a 0.5 McFarland standard inoculum was used.
If the presence of EDTA inhibited imipenemase activity, the organism was categorized as MBL-positive. These isolates underwent genotypic testing to confirm the presence of an MBL gene. The antibiotic MICs of all confirmed isolates were determined using broth microdilution according to the Clinical and Laboratory Standards Institute (i.e., NCCLS) guidelines [15, 16] . Only the first resistant isolate of a given genus from each patient was included in the study. Of the included isolates, those of the same genus underwent ribotyping with the automated RiboPrinter Microbial Characterisation System (Qualicon) using the restriction enzymes EcoR1 (for Enterobacteriaceae) or PVUII (for P. aeruginosa), as recommended by the manufacturer. We also examined, in a single patient, the riboprint pattern of an Enterobacter cloacae isolate before and after the detection of an MBL gene.
PCR analysis was performed with primers specific for bla VIM [17, 18] and bla IMP [7, 18] . DNA sequencing was performed with ABI Prism Big Dye Terminator Cycle sequencing (Applied Bioscience) and the ABI Prism 3700 (Applied Biosystems) automated sequencer. Primers to amplify the entire sequence of the bla IMP-4 gene were used [18] . DNAMAN sequence analysis software (Lynnon Biosoft) was used for alignment of DNA sequences and deduced amino acid sequences. The presence of class 1, 2, or 3 integrons was detected by PCR amplification of an integrase-specific fragment of the IntI1, IntI2, and IntI3 genes, respectively [19] .
Medical records of patients with confirmed isolation of MBLproducing organisms were reviewed for clinical and epidemiological data. The clinical significance of each isolate (i.e., whether it represented infection or colonization) was determined. Infection was defined as either (1) the presence of an acute systemic inflammatory response together with local symptoms or signs of infection, including purulent sputum and pyuria [8] ; or (2) isolation of an organism from a sterile site. 
RESULTS

From
NOTE. Drug susceptibilities were interpreted according to the Clinical Laboratory Standards Institute (i.e., NCCLS) interpretive standard [15] . -, No interpretive guideline; Amk, amikacin; Azt, aztreonam; Caz, ceftazidime; Cip, ciprofloxacin; Cpm, cefepime; Gen, gentamicin; I, intermediate; Imi, imipenem; Pol, polymyxin B; R, resistant; S, sensitive; Tic-Clv, ticarcillin-clavulanate; TMP-SMX, trimethoprim-sulfamethoxazole; Tob, tobramycin.
cloacae isolates. Resistance to non-b-lactam antibiotics, including aminoglycosides, quinolones, and sulphonamide derivatives, was variable. All isolates were susceptible to polymyxin B except for the S. marcescens isolates, which have intrinsic resistance to this antimicrobial agent.
The clinical characteristics of the 16 patients from whom bla IMP-4 -positive gram-negative organisms were isolated are summarized in table 2. The median age was 45 years (range, 17-85 years) and 9 patients (56%) were male. Eight patients (50%) had no underlying disease prior to admission. Two patients (patients 1 and 12) had non-Hodgkin lymphoma, 3 (patients 6, 11, and 16) had type 2 diabetes mellitus, 2 (patients 10 and 15) were receiving prednisolone therapy, and 1 (patient 14) had congenital heart disease. Twelve patients (75%) received a carbapenem prior to the isolation of an MBL-producing organism, with a median duration of treatment of 13 days (range, 3-23 days). The remaining 4 patients received broad-spectrum b-lactam antibiotics, including cephalosporins and b-lactamb-lactamase inhibitor combinations.
All isolates were considered hospital-acquired. Of the 19 isolates carrying the bla IMP-4 gene, 8 (42%) were isolated from the respiratory tract, which was the predominant source: 7 isolates were recovered from sputum samples and 1 from a bronchioalveolar lavage fluid specimen. Four isolates (21%) were recovered from urine cultures, and the remaining 7 isolates were recovered from blood cultures ( ), wound cultures n p 3 ( ), and a central venous catheter-tip culture ( ). In n p 3 n p 1 total, bla IMP-4 -positive gram-negative organisms caused infection in 75% of cases. Five isolates were associated with ventilator-associated pneumonia, 3 were associated with septicemia, 1 was associated with urinary tract infection, and 1 was associated with superficial central venous line infection. Of the 3 urinary isolates representing colonization, 2 were associated with subsequent septicemia. Six (38%) of the 16 patients from whom an MBL-producing organism was isolated died; 5 of those 6 (31% of the group of 16) had clinical infection with an MBL-producing organism. Three patients died with septicemia; in 2 of these 3 (patients 1 and 16), the primary source of bactermia was central venous catheter-related infection (with P. aeruginosa and S. marescens, respectively), and in 1 of the 3 (patient 10), the source was urinary colonization with P. aeruginosa. Patient 1 received empirical therapy with ciprofloxacin and teicoplanin, and patient 10 received empirical therapy with cefazolin, but both died before organism identification. Patient 16 received empirical therapy with ciprofloxacin, to which the organism was resistant, and died before susceptibility results were available. The remaining 2 patients (6 and 9) died with ventilator-associated pneumonia (in both cases due to S. marcescens), and patient 6 also had intra-abdominal sepsis. Patient 6 was initially treated with ciprofloxacin, tobramycin, and ceftazidime, and then treatment was changed to colistin and vancomycin. The treatment history for patient 9 was incomplete.
Seven patients with clinical infection survived. Of the 3 pa- tients treated successfully for ventilator-associated pneumonia, 1 (patient 4) was treated with gentamicin and ciprofloxacin, 1 (patient 5) was treated with trimethoprim-sulfamethoxazole and tobramycin, and 1 (patient 13) was treated with ciprofloxacin. Of the 2 patients treated successfully for septicemia, 1 (patient 8) received colistin followed by amikacin for P. aeruginosa infection, and 1 (patient 11) received ciprofloxacin for K. pneumoniae. A superficial central venous catheter site infection in patient 2 and a urinary tract infection in patient 15 were both successfully treated with line removal and norfloxacin, respectively. The epidemiology of the outbreak is shown in figure 1 . The median hospital and ICU lengths of stay were 69 days (range, 7-173 days) and 34 days (range, 0-124 days ), respectively. The median time from hospital admission to isolation of an MBLproducing organism was 29 days (range, 0-48 days). All patients except patients 12 and 15 had spatio-temporal epidemiological links in the ICU. Patient 12 had had 2 admissions to a burn ward; on the day of the second admission, an MBL-positive S. marcescens strain was isolated. Patient 8 was in the same burn ward throughout this time and was carrying an MBL-positive strain of P. aeruginosa. Patient 12 also had had a 3-week stay in the ICU 6 months before. Patient 15 was an inpatient in a respiratory ward at the time of isolation of an MBL-positive strain of K. pneumoniae. Four months earlier, patient 3 had been an inpatient in the same ward and was carrying an MBLpositive strain of S. marcescens. Overall, no pattern of gene transfer between genera was identified. Two patients (11 and 13) had multiple genera of bla IMP-4 -positive gram-negative pathogens isolated during a single hospital stay.
The ribotyping results are shown in figure 2 . All K. pneumoniae isolates were of different ribogroups. In contrast, all except 1 S. marcescens isolate and all of the P. aeruginosa isolates (ribogroup 127-415-S-1, data not shown) were of the same ribogroup. The E. cloacae strains isolated from the same patient before and after bla IMP-4 detection were of the same ribogroup.
DISCUSSION
Carbapenems play a critical role in the management of severe hospital-acquired infections and are often used as an antibiotic of last resort. The emergence of gram-negative pathogens with acquired MBLs that mediate carbapenem resistance is a worrying development. This concern is compounded by the paucity of antibacterial drugs being developed to target gram-negative organisms [20] . To our knowledge, this is the first study to illustrate the ease of dissemination of an MBL gene among 5 different gram-negative genera in a clinical setting. It is also the first clinical outbreak of infection with MBL-producing organisms in Australia, a continent that only recently described the presence of this resistance mechanism [14] . Other unique features of this outbreak include the high rate of clinical infection and the detection of the bla IMP-4 gene in isolates of S. marcescens and E. cloacae. A total of 19 isolates from 16 patients were identified over a 7-month period, representing 0.9% of gram-negative isolates. All isolates were found to carry the bla IMP-4 gene, a resistance gene previously reported in Hong Kong and China [1, 11] , and were found to have 95.6% amino acid homology with the first described MBL gene, bla IMP-1 [1] .
The emergence of the bla IMP-4 gene at our institution was rapid, and the majority of patients had strong epidemiological links. The most commonly isolated organism was S. marcescens (10 isolates), followed by K. pneumonia (4 isolates), P. aeruginosa (3 isolates), E. cloacae (1 isolate) and E. coli (1 isolate). Of particular interest, patients with temporal links in the ICU most often had isolates of different genera. Also, bla IMP-4 -carrying isolates of multiple gram-negative genera were recovered from 2 patients during a single hospitalization. With regard to the ribotyping data, all K. pneumoniae isolates were unique strains, and the E. cloacae isolates recovered from a single patient before and after bla IMP-4 detection, were the same strain; both of these findings suggest horizontal gene acquisition. In contrast, all S. marcescens isolates except 1 were the same strain and all P. aeruginosa isolates were the same strain, suggesting nosocomial transmission. Given the observed clinical and molecular epidemiology and the presence of a class 1 integron in all isolates, it would appear that horizontal gene transfer between genera was occurring. This important hypothesis needs further confirmation with integron characterization, mobile genetic element assessment, and gene transfer experiments.
Of the 19 bla IMP-4 -positive isolates, only 5 (26%) were found to be carbapenem-resistant (MIC 18 mg/L). Seven isolates (37%) tested sensitive to imipenem (MIC р4 mg/L), including 2 isolates of S. marcescens, 4 isolates of K. pneumoniae, and 1 isolate of E. coli (table 1) . This variable carbapenem susceptibility has been described previously [21, 22] and can be explained by a number of factors. Firstly, phenotypic expression of resistance is more likely when other resistance mechanisms are present. For example, the uniform appearance of carbapenem resistance in our P. aeruginosa isolates most likely represents the copresence of up-regulated efflux pumps and/or membrane impermeability [23] . Other explanations include suppressed MBL gene expression by secondary regulatory systems, leading to a silent or cryptic bla IMP gene [7] , and varied carbapenem hydrolysis depending on the MBL gene dosage effect, which relates to the plasmid copy number [8] . Given the importance of early recognition, diagnostic laboratories must use more sensitive means of screening, such as those described in this and other studies [24] . Also, if available, molecular screening should be used to enable rapid detection of this emerging b-lactamase.
Aztreonam susceptibility is a common feature of MBL-producing organisms and was found in 15 (79%) of our isolates. It was not evident in our P. aeruginosa and E. cloacae isolates, most likely due to the presence of derepressed AmpC b-lactamases. The clinical utility of aztreonam in treating human infections caused by MBL-producing organisms has not been studied. Data from animal studies suggest that aztreonam at high doses may be effective [25] . Given the limited therapeutic options and the potential severity of infection, aztreonam may become a more common part of our armamentarium.
Few studies describe the clinical characteristics of infections caused by MBL-producing organisms [8, [26] [27] [28] ; the majority of those that do report high rates of colonization [8, 26, 28] . In the current study, 12 patients (75%) experienced clinical infection, with ventilator-associated pneumonia and septicemia being the most common. Fifty percent of patients had no preexisting illness. This finding is in contrast to the findings of previous studies, which have reported higher rates of underlying malignancy [8, 28, 29] or comorbid illness [27] . Overall, 38% of patients died in the hospital. This may relate to the patient population, but of the 6 patients who died, 5 were infected with an MBL-producing organism; 3 had septicemia and 2 had ventilator-associated pneumonia.
The clinical implications of this study are of concern. The bla IMP-4 gene, which mediates resistance to broad-spectrum blactams, has now emerged in a new continent. Therapeutic options are limited and the roles of aztreonam and colistin therapy are uncertain. The apparent ease of MBL gene dissemination between gram-negative genera warrants further research to help devise means of prevention. Diagnostic laboratories in Australia and other countries must now be on high alert, because early detection may limit the wide dispersal of MBL genes. Implementation of strict infection control practices and the prudent and cautious use of carbapenems are also critical if we are to preserve the longevity of these invaluable antimicrobial agents.
